Aggregation-resistant alpha-synuclein tetramers are reduced in the blood of Parkinson's patients

EMBO Mol Med. 2024 Jul;16(7):1657-1674. doi: 10.1038/s44321-024-00083-5. Epub 2024 Jun 5.

Abstract

Synucleinopathies such as Parkinson's disease (PD) are defined by the accumulation and aggregation of the α-synuclein protein in neurons, glia and other tissues. We have previously shown that destabilization of α-synuclein tetramers is associated with familial PD due to SNCA mutations and demonstrated brain-region specific alterations of α-synuclein multimers in sporadic PD patients following the classical Braak spreading theory. In this study, we assessed relative levels of disordered and higher-ordered multimeric forms of cytosolic α-synuclein in blood from familial PD with G51D mutations and sporadic PD patients. We used an adapted in vitro-cross-linking protocol for human EDTA-whole blood. The relative levels of higher-ordered α-synuclein tetramers were diminished in blood from familial PD and sporadic PD patients compared to controls. Interestingly, the relative amount of α-synuclein tetramers was already decreased in asymptomatic G51D carriers, supporting the hypothesis that α-synuclein multimer destabilization precedes the development of clinical PD. Our data, therefore suggest that measuring α-synuclein tetramers in blood may have potential as a facile biomarker assay for early detection and quantitative tracking of PD progression.

Keywords: Alpha-synuclein; Blood; Human; Parkinson’s disease; Tetramer.

MeSH terms

  • Aged
  • Female
  • Humans
  • Male
  • Middle Aged
  • Parkinson Disease* / blood
  • Parkinson Disease* / genetics
  • Parkinson Disease* / metabolism
  • Protein Aggregates
  • Protein Multimerization
  • alpha-Synuclein* / blood
  • alpha-Synuclein* / metabolism

Substances

  • alpha-Synuclein
  • Protein Aggregates
  • SNCA protein, human